e-Therapeutics plc has unveiled new patent filings to protect its proprietary RNAi platform technology for liver gene silencing.
The computational drug discovery specialist recently filed five new patent applications relating to its GalNAc-conjugated siRNA (short interfering RNA) construct designs, including for stabilising chemical modifications enabling specific hepatocyte (liver cell) targeting.
READ: e-therapeutics to make US debut on OTCQX Best Market today
"Since our capital raise in May, we have made excellent progress in all areas of the company,” said chief executive Ali Mortazavi.
“We expect to present data from our RNAi platform in our interim results announcement on Tuesday 26 October, when the in vivo characterisation studies will have been completed."
Shares jumped 11% to 33.81p early on Monday.